Access in all areas? A round up of developments in market access and HTA: part 5
Publication: Journal of Comparative Effectiveness Research
Abstract
In this latest update, we explore the recent announcement by Canada's Drug Agency (CDA-AMC, formerly CADTH) on their pilot to include the societal perspective in the evaluation of certain new medicines; a recent Office of Health Economics (OHE) report on the evaluation of HTA agency methods over time; and publications examining the impact of Project Orbis on patient access to oncology treatments.
Formats available
You can view the full content in the following formats:
References
1.
Canada's Drug Agency – L'Agence des médicaments du Canada (CDA-AMC). Piloting the Addition of New Perspectives to Economic Evaluations of Drugs. https://www.cda-amc.ca/news/piloting-addition-new-perspectives-economic-evaluations-drugs
2.
Canada's Drug Agency – L'Agence des médicaments du Canada (CDA-AMC). Procedures for Reimbursement Reviews. https://www.cda-amc.ca/sites/default/files/Drug_Review_Process/CADTH%20Drug%20Reimbursement%20Review%20Procedures.pdf
3.
Lin P-J, Neumann PJ. Valuing Alzheimer disease therapies – considering costs and benefits beyond the patient. JAMA Netw. Open 4(10), e2131913 (2021).
4.
Shafrin J, Skornicki M, Brauer M et al. An exploratory case study of the impact of expanding cost–effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: does it make a difference? Health Policy 122(6), 607–613 (2018).
5.
Shafrin J, Thahir S. Quantifying the insurance value for rare diseases: duchenne muscular dystrophy. Am. J. Manag. Care 30(7), e217–e222 (2024).
6.
Radu P, Kumar G, Cubi-Molla P et al. Navigating change: a comparative analysis across health technology assessment agencies on their positions on five key topics. OHE Contract Research Report, Office of Health Economics, UK (2024).
7.
Cohen JT. It is time to reconsider the 3% discount rate. Value Health 27(5), 578–584 (2024).
8.
Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.0). https://pbac.pbs.gov.au/content/information/archived-versions/pbac-guidelines-v4-2006.pdf
9.
Zosso-Pavic M, Li Q, Atiek E, Wolfer A, Rohr U-P. Effect of Project Orbis participation by the Swiss regulator on submission gaps, review times, and drug approval decisions between 2020 and 2022: a comparative analysis. Lancet Oncol. 25(6), 770–778 (2024).
10.
Jenei K, Gentilini A, Haslam A, Prasad V. Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis. Lancet Oncol. 25(8), 979–988 (2024).
Information & Authors
Information
Published In
Copyright
© 2024 The Authors. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 3 September 2024
Accepted: 13 September 2024
Published online: 1 October 2024
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Access in all areas? A round up of developments in market access and HTA: part 5. (2024) Journal of Comparative Effectiveness Research. DOI: 10.57264/cer-2024-0179
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Annie Jullien Pannelay, Ramiro E Gilardino, Sreeram V Ramagopalan, Access in all areas? A roundup of developments in market access and health technology assessment: part 6, Journal of Comparative Effectiveness Research, 10.57264/cer-2024-0239, 14, 3, (2025).